iBio’s technology stack is designed to deliver next-generation precision antibodies for difficult targets and modes of action with the potential for high developability and enhanced safety. Powered by machine learning, our platform combines epitope steering, antibody optimization for monoclonal antibodies and CD3 T-cell engager bispecfics, and antibody masking, to overcome key challenges in discovery and development.
Our team of computational biologists and highly skilled drug hunters are engineering antibodies for hard-to-drug targets to support rapid pipeline growth and maturation. We have a pipeline of 6 biologics, primarily focused on immuno-oncology. Through our strategic partnership with AstralBio, we are developing molecules for obesity, diabetes, and heart disease. Our cardiometabolic program focuses on leveraging validated biology to develop first-in-class and best-in-class molecules that counter some of the shortcomings of current therapeutics in the incretin class, including bone and muscle loss. We also see potential in novel targets that enhance compliance by offering lower dosage frequency and improve efficacy with an extended half-life.
Driven by our commitment to innovation, we are developing select programs internally while maintaining the flexibility to explore collaborative opportunities through licensing our programs to strategic partners.
We are excited about the potential therapeutic benefits of our proprietary pipeline and are looking for partners who share our passion for bringing innovative treatments to advance healthcare and improve patient lives.
To learn more about our pipeline candidates and potential partnership opportunities, please contact us.
